CAMBRIDGE, MA, According to SEC filings, Cambridge-based vaccine developer Variation Biotechnologies Inc. has raised a combined $7.8 million in a pair of debt financings. One funding was for $3.5 million in debt and options or warrants for securities, and the second was for $4.3 million.

Variation Biotechnologies is a vaccine development company dedicated to the innovative formulation, development and delivery of thermostable vaccines that expand and enhance vaccine protection in both established and emerging markets. VBI's innovative approach to vaccine development and growing pipeline of vaccine programs address significant market opportunity and are designed to answer critical unmet medical need.